Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 27

1.

Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease.

Kistler KD, Brunt EM, Clark JM, Diehl AM, Sallis JF, Schwimmer JB; NASH CRN Research Group.

Am J Gastroenterol. 2011 Mar;106(3):460-8; quiz 469. doi: 10.1038/ajg.2010.488. Epub 2011 Jan 4.

2.

Role of liver biopsy in nonalcoholic fatty liver disease.

Nalbantoglu IL, Brunt EM.

World J Gastroenterol. 2014 Jul 21;20(27):9026-37. doi: 10.3748/wjg.v20.i27.9026. Review.

3.

Histopathology of nonalcoholic fatty liver disease.

Brunt EM, Tiniakos DG.

World J Gastroenterol. 2010 Nov 14;16(42):5286-96. Review.

4.

Can NASH be diagnosed, graded, and staged noninvasively?

Grandison GA, Angulo P.

Clin Liver Dis. 2012 Aug;16(3):567-85. doi: 10.1016/j.cld.2012.05.001. Epub 2012 Jun 26. Review.

5.

[Non-alcoholic fatty liver disease--new view].

Raszeja-Wyszomirska J, Lawniczak M, Marlicz W, MiezyƄska-Kurtycz J, Milkiewicz P.

Pol Merkur Lekarski. 2008 Jun;24(144):568-71. Review. Polish.

PMID:
18702346
6.

Managing nonalcoholic fatty liver disease: recommendations for family physicians.

Grattagliano I, Portincasa P, Palmieri VO, Palasciano G.

Can Fam Physician. 2007 May;53(5):857-63. Review.

7.

Recommendations for liver biopsy evaluation in non-alcoholic fatty liver disease.

Stinton LM, Loomba R.

Minerva Gastroenterol Dietol. 2014 Mar;60(1):5-13. Review.

PMID:
24632764
8.

Nonalcoholic fatty liver disease: a systematic review.

Rinella ME.

JAMA. 2015 Jun 9;313(22):2263-73. doi: 10.1001/jama.2015.5370. Review. Erratum in: JAMA. 2015 Oct 13;314(14):1521.

PMID:
26057287
9.

Association of obstructive sleep apnoea with the presence and severity of non-alcoholic fatty liver disease. A systematic review and meta-analysis.

Musso G, Cassader M, Olivetti C, Rosina F, Carbone G, Gambino R.

Obes Rev. 2013 May;14(5):417-31. doi: 10.1111/obr.12020. Epub 2013 Feb 6. Review.

PMID:
23387384
10.

Liver fibrosis markers of nonalcoholic steatohepatitis.

Enomoto H, Bando Y, Nakamura H, Nishiguchi S, Koga M.

World J Gastroenterol. 2015 Jun 28;21(24):7427-35. doi: 10.3748/wjg.v21.i24.7427. Review.

11.

Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies.

Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R.

Clin Gastroenterol Hepatol. 2015 Apr;13(4):643-54.e1-9; quiz e39-40. doi: 10.1016/j.cgh.2014.04.014. Epub 2014 Apr 24. Review.

12.

Recommendations for Diagnosis, Referral for Liver Biopsy, and Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.

Spengler EK, Loomba R.

Mayo Clin Proc. 2015 Sep;90(9):1233-46. doi: 10.1016/j.mayocp.2015.06.013. Epub 2015 Jul 26. Review.

PMID:
26219858
13.

Nonalcoholic fatty liver disease in children: recent practice guidelines, where do they take us?

Aggarwal A, Puri K, Thangada S, Zein N, Alkhouri N.

Curr Pediatr Rev. 2014;10(2):151-61. Review.

PMID:
25088269
14.

Nonalcoholic fatty liver disease: updates in noninvasive diagnosis and correlation with cardiovascular disease.

Hu KC, Wang HY, Liu SC, Liu CC, Hung CL, Bair MJ, Liu CJ, Wu MS, Shih SC.

World J Gastroenterol. 2014 Jun 28;20(24):7718-29. doi: 10.3748/wjg.v20.i24.7718. Review.

15.

Nonalcoholic fatty liver disease: pathologic patterns and biopsy evaluation in clinical research.

Kleiner DE, Brunt EM.

Semin Liver Dis. 2012 Feb;32(1):3-13. doi: 10.1055/s-0032-1306421. Epub 2012 Mar 13. Review.

PMID:
22418883
16.

Cytokeratin-18 fragments and biomarkers of the metabolic syndrome in nonalcoholic steatohepatitis.

Yilmaz Y, Kedrah AE, Ozdogan O.

World J Gastroenterol. 2009 Sep 21;15(35):4387-91. Review.

17.

Progress in the search for circulating biomarkers of nonalcoholic fatty liver disease.

Amacher DE.

Biomarkers. 2014 Nov;19(7):541-52. doi: 10.3109/1354750X.2014.958535. Epub 2014 Sep 5. Review.

PMID:
25189636
18.

Development of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) after pancreaticoduodenectomy: proposal of a postoperative NAFLD scoring system.

Kato H, Isaji S, Azumi Y, Kishiwada M, Hamada T, Mizuno S, Usui M, Sakurai H, Tabata M.

J Hepatobiliary Pancreat Sci. 2010 May;17(3):296-304. doi: 10.1007/s00534-009-0187-2. Epub 2009 Oct 7. Review.

PMID:
19809782
19.

Endpoints and clinical trial design for nonalcoholic steatohepatitis.

Sanyal AJ, Brunt EM, Kleiner DE, Kowdley KV, Chalasani N, Lavine JE, Ratziu V, McCullough A.

Hepatology. 2011 Jul;54(1):344-53. doi: 10.1002/hep.24376.

20.

Have guidelines addressing physical activity been established in nonalcoholic fatty liver disease?

Finelli C, Tarantino G.

World J Gastroenterol. 2012 Dec 14;18(46):6790-800. doi: 10.3748/wjg.v18.i46.6790. Review.

Items per page

Supplemental Content

Write to the Help Desk